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USA to share the latest development in research and clin-
ical treatment of breast cancer. The recent symposium held
in December 2015 was another exciting mix of translational
research and clinical presentations that further advances
the field of breast cancer understanding and management.
In this article we will review selected abstracts that we feel
will have future impact on breast cancer research and
clinical practice. We will initially cover those presentations
that impact our understanding of breast cancer biology andand hosting by Elsevier B.V. This is an open access article under the
4.0/).
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tial to influence and alter clinical practice.
Several of the presentations assessed the impact and
role of tumor infiltrating lymphocytes (TILs) and expands
our understanding of this interesting pathologic finding. A
recent meta-analysis has shown that high levels of FOXP3þ
TILs are associated with improved recurrence-free survival
(RFS) and overall survival (OS) of patients with triple
negative breast cancer (TNBC). Just the opposite effect
was seen in the hormone receptor positive patient with
increased TILs being associated with a worse RFS and OS.1
In the HER2þ subset increase in TILs has been associated
with an increase in pathologic complete response rate
(pCR) in the neoadjuvant chemotherapy (NAC) combined
with anti-HER2 directed therapy. And this has correlated
with an improved RFS and OS.2 Efforts to standardize TIL’s
have recently been published and validated.3,4
Dr. Molinero presented retrospective analyses of mo-
lecular markers of the tumor immune and stromal micro-
environment from the BEATRICE study. This was an
adjuvant study in TNBC that compared chemotherapy to
chemotherapy with bevacizumab. This study was negative
for any benefit of bevacizumab but provided a large tumor
repository to perform additional testing. They showed that
gene signatures that correlated with increased TILs and
especially increased CD 8 effector T cells showed an
improved invasive disease free survival (IDFS) and OS. They
also demonstrated that increased stromal cell gene
expression was associated with a negative effect on IDFS
and OS. Dr. Loi presented pooled data from several ran-
domized clinical trials of TNBC patients (991 patients)
treated with anthracycline based adjuvant chemotherapy
and showed that increasing TILs were associated with an
improved IDFS and OS. They also demonstrated that there
was a continuous association such that every increase in
TILs by 10% was associated with a 12% reduction of risk of
recurrence in patients.
Dr. Desmedt group look at the expression of TILs in a
large cohort of patients with invasive lobular carcinoma.
Unlike the HER2þ and TNBC subgroups the increased
expression of TILs was associated with a worsening prog-
nosis. However the overall expression of TILs in this group
of patients was fairly low (median 5%) and only 15% of pa-
tients had TILs greater than 10%. Increased TILs when
present was associated with classical poor prognostic
pathologic markers such as node positivity, high tumor
grade and increased tumor size. This supports the idea that
the ERþ group of tumors for the most part is less immu-
nogenic than the more aggressive subtypes of breast
cancer.
Several of the oral presentations examined preclinical as
well as clinical data on mutations of the gene coding for the
estrogen receptor alpha (ESR1). ESR1 mutations are un-
common in primary breast cancer however with endocrine
therapy activating mutations of the ESR1 occur and lead to
ligand-independent ER activation and endocrine resis-
tance.5 More recently cell free DNA (cfDNA) from the
plasma has allowed for a non-invasive method to detect the
development of these mutations.6,7 Using cfDNA of plasma
samples from the BOLERO-2 study showed a high incidence
(29%) of the two most common mutations of the ESR1
(Y537S, D538G). Both mutations were associated with ashorter OS. Also they showed a beneficial effect of ever-
olimus in patients with the wild type (WT) ESR1 and the
D538G mutation but not the Y537S mutation. Another pre-
sentation by Dr. Gellert using paired primary and meta-
static tumor specimens showed that estrogen deprivation
with an aromatase inhibitor produced an increase in ESR1
mutations with the incidence in the primary tumor being
very low as previously reported.
The last area in the diagnostic arena that was looked at
was circulating tumor cells (CTCs). This was an update of
the previously reported SUCCESS, a study that showed the
number of CTCs both before and after adjuvant chemo-
therapy in a large prospective trial of patients with primary
breast cancer was an independent prognostic marker.8 All
patients received an anthracycline and taxane based
adjuvant chemotherapy protocol and hormonal therapy for
endocrine responsive tumors. There were randomizations
to gemcitabine and duration and schedule of zoledronate as
part of the protocol. Dr. Janni presented the data on the
analysis of CTCs that was assessed 2 years after study entry.
They found that 18.2% of patients had at least 1 persistent
CTCs and this correlated independently for RFS and OS.
They suggested that this may allow at some point the
introduction of possible delayed treatment options that
could alter the poorer prognosis for this group of patients.
Several oral presentations revolved around adjuvant
treatment. Dr. Nielsen presented a look back at an older
Danish study, DBCG77B which randomized patients to no
chemotherapy, classical CMF or oral cyclophosphamide.
The study overall was positive for the chemotherapy arms
vs the control arm. All patients were either node positive or
had T3 primaries. They went back and using a panel of
immunohistochemical stains, defined a subgroup of pa-
tients as luminal A. They showed that this group despite
being higher risk derived no benefit from adjuvant chemo-
therapy. Additionally patients with the luminal A subtype
even in the control arm had a better prognosis than the
other defined groups. This is concordant with several other
retrospective analyses of other randomized trials (NSABP
20, IBCSG 8 and 9). This also agrees with the recent publi-
cation of the non-randomized arm of TAILORx that showed
patients with low recurrence score risk did well despite no
chemotherapy. The rate of freedom from recurrence of
breast cancer at a distant site was 99.3% at 5 years of
follow-up. One would assume most of these patients are
luminal A subtype.9 Currently, there is no randomized trial
to address the question if we can safely omit adjuvant
chemotherapy in high risk patients with early breast cancer
who have the luminal A histology.
One of the potentially practice changing studies was
presented by Dr. Gnant and was the survival analyses of
ABCSG-18. This was a placebo double blind study that
randomized 3425 patients who were postmenopausal and
ER positive that were being treated with an aromatase in-
hibitor to denosumab 60 mg SQ every 6 months or placebo.
This study has previously been shown to reduce the fracture
rate by 50%.10 There was a 4% absolute reduction in
recurrence in the treated arm vs the control, just outside
the level of statistical significance. This is very similar to
the benefit seen with bisphosphonates in the EBCTCG meta-
analyses where a 3% absolute difference was seen with the
use of bisphosphonates.10 So this may give us another
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and recurrence risk in postmenopausal patients, especially
those who have high risk early breast cancer. Also denosu-
mab can be used in patients with chronic kidney disease
where one would not wish to use the other agents.
The 10-year update by Dr. Slamon of BCIRG-006
continued to show a similar benefit of the TCH (doce-
taxol, carboplatin, and trastuzumab) compared to that of
AC-TH (Adriamycin/cyclophosphamide with docetaxel and
trastuzumab), in all patients as well as the high risk subsets
(node positive or those with 4 or more positive nodes).
There continues to be a fewer secondary leukemias and
congestive heart failure in the non-anthracycline contain-
ing arm as initially reported.
In the area of immunotherapy there were several pre-
sentations evaluating a number of the checkpoint inhibitors
in metastatic breast cancer. Dr. Dirix presented the Phase
1b data on Avelumab, an investigational anti-PD-L1 inhibi-
tor in 168 patients with metastatic breast cancer. The ac-
tivity was low with only 1 CR and 7 PR with a response rate
of 4.7%. The activity was higher in the TNBC patients with a
RR of 8.6%. They observed higher activity in the patients,
with increased PD-L1 staining of tumor-associated immune
cells. Dr. Rugo then presented the data from the KEYNOTE-
028 study testing the anti PD-1 antibody pembrolizumab
given on an every 2 week schedule. In the 25 patients in the
breast cancer cohort that had positive staining for anti-PD-
L1 there was a RR of 12% and clinical benefit rate of 20%.
Thus we see there appears to be modest activity of these
checkpoint inhibitors in patients with metastatic breast
cancer, especially those who have triple negative breast
cancer. However some of the responses were durable and
ongoing. There is the potential to combine these agents
with other biologics and chemotherapy that may increase
the activity of this class of agents. Additional biomarkers
continue to need to be explored to help determine the most
appropriate patients for these new agents.
There were two randomized studies that assessed the
addition of carboplatin in the neoadjuvant setting. The
GeparSixto trial tested the addition of carboplatin weekly
(initially AUC of 2 reduced to 1.5) to a novel induction
regiment of weekly paclitaxel, weekly non-pegylated lipo-
somal doxorubicin and every 3 week bevacizumab for 18
weeks in patients with TNBC and HER2-positive early breast
cancer. In the HER2-positive patient there was no benefit in
pCR rates but in the TNBC patients there was a marked
increase in pCR from 36.9% to 53.2%. This effect was
translated into a statistically significant improvement of 3
year DFS in the TNBC group independent of BRCA status.
The other study CALGB 40603 was a 2  2 randomization of
bevacizumab and carboplatin to a neoadjuvant induction of
weekly paclitaxel for 12 weeks followed by dose-dense
doxorubicin and cyclophosphamide for 4 cycles in TNBC
patients with Stage IIeIII disease. Carboplatin was dosed
every 3 weeks at an AUC of 6. As has been seen previously,
pCR correlated with an improved 3-year EFS and OS. This
study failed to demonstrate any EFS or OS benefit to bev-
acizumab or carboplatin although the investigators did
state the study was underpowered to firmly answer this
question. It is not clear why the outcomes were better with
GeparSixto unless there may be some advantage to giving
carboplatin weekly. However, the absence of an alkylator inthe chemotherapy backbone of this study could have
explained the benefit of platinum. There are not enough
data to be conclusive at this time. Are there times that
addition of carboplatin can be considered for neoadjuvant
treatment in TNBC outside a clinical trial? Possibly for a
patient who is young with advanced stage disease who
needs a rapid local control of their disease. There is sig-
nificant increase in myelosuppression with the addition of
carboplatin to our traditional AC/T induction treatment,
and this has been shown to attenuate the delivered dose
intensity of paclitaxel. Additional ongoing clinical trials of
neoadjuvant and adjuvant platinum salts will hopefully
answer this question. Finally the WSG-ADAPT TN random-
ized phase II trial was presented that compared a 12 week
induction protocol of carboplatin AUC 2 D1 and D8 every 21
days for 4 cycles with either gemcitabine 1000 mg/M2 D1
and D8 or nab-paclitaxel 125 mg/M2 D1 and D8 in patients
with TNBC. The pCR rate with the nab-paclitaxel/
carboplatin was 45.9% without the use on an anthracy-
cline in just 4 cycles which is impressive. No DFS or OS in
this study was available at this time.
One interesting study presented was the CREATE-X study
which was a large phase III study of adjuvant capecitabine
in HER2-negative breast cancer in patients who had residual
invasive disease after neoadjuvant chemotherapy. Patients
were randomized to initially 6 and later 8 cycles of cape-
citabine 2500 mg/M2/day for 14 out of 21 days after neo-
adjuvant chemotherapy with an anthracycline and taxane
or TC with a non-pCR. Eighty percent of the patients
received sequential AeT type therapy. All ER positive pa-
tients had endocrine therapy as well. The 5 year DFS
improved from 67.7% to 74.1% and OS improved from 83.9%
to 89.2%, both statistically significant. The most prominent
hazard ratio (HR) was seen in the TNBC subgroup. Other
studies have shown positive effects of adjuvant capecita-
bine added to standard chemotherapy in the TNBC sub-
groups, although it was given in different doses with other
agents. The USON 01062 saw a benefit in OS in the TNBC
subgroup11 and similar effect was seen in the TNBC sub-
group of FinXX.12
In the area of management of DCIS updated information
was presented on NSABP B-35. This study compared anas-
trozole to tamoxifen in postmenopausal patient with ER or
PR positive DCIS treated with lumpectomy and radio-
therapy. Overall the breast cancer-free (BCFI) interval was
improved with anastrozole over tamoxifen from 89.2% to
93.5%. The bulk of this improvement was seen in patients
under the age of 60. This presentation looked in detail at
the patient reported outcomes and showed a definite dif-
ference in side effects between the two treatments.
Vasomotor symptoms appeared worse with tamoxifen while
musculoskeletal symptoms were worse with anastrozole.
Vaginal symptoms were worse with anastrozole while
bladder control problems were increased in patients on
tamoxifen. There was no difference in sexuality functioning
scores, cognitive issues or weight control problems be-
tween the two drugs. However, vasomotor symptoms,
weight problems and vaginal symptoms were worse in the
patients under 60 years of age. With the information on the
toxicity profile of the agents the BCFI patients and their
physicians can now make personalized decisions about
which of these two effective agents to select in this setting.
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which randomized 2980 postmenopausal patients with DCIS
to anastrozole or tamoxifen for 5 years. There was a trend
favoring anastrozole in reduction of breast cancer recur-
rence but it was not statistically significant with 7.2 years
of median follow-up. Compliance to both agents was
equivalent with 2/3 of patients completing 5 years of
therapy. Toxicity profile was as anticipated with a noted
exception being a significant increase in carpel tunnel seen
in the patients on anastrozole and decrease in endometrial,
ovarian and skin cancers seen with anastrozole.
Dr. Taylor for the EBCTCG presented an analysis of the
long term effects of radiotherapy in relationship to the
development of lung cancer and ischemic heart disease.
They showed the doses today to the heart and lung are
significantly less than the averages in the trials and even
less in the more modern radiotherapy trials. Using data
from the trials and assigning a value of excess risk per Gy
they showed that with current breast treatment protocols
the increase in lung cancer in nonsmokers is minimal but
even with current techniques there is a marked increase of
risk in smokers, going from 9.4% to 13.8% by age 80 when
radiation is given at age 50. Minimal increase of the risk of
heart disease is seen in non-smokers (1.8%e2.0%) and
slightly more in smokers (8.0%e8.6%). The take home
message is that patients who are smokers and have breast
cancer who are going to require radiation therapy should be
strongly encouraged to enter a smoking cessation program
since the risk is very much delayed and therefore could be
avoided. These data can provide further information to
help reinforce that plan.
Finally the MANTICORE study was presented that looked
at the utility of using either a beta-blocker or an ACE in-
hibitor to reduce the risk of cardiotoxicity in patients with
early stage HER2 positive breast cancer receiving
trastuzumab-based chemotherapy. This was a 3-arm study
that was double blinded and placebo controlled. The pri-
mary endpoint was change in indexed left ventricular end-
diastolic volume by cardiac MRI following 17 cycles of
trastuzumab with secondary outcome being change in left
ventricular ejection fraction (LVEF) by the same technique.
Both interventional arms had a marked reduction in dose
interruptions of trastuzumab compared to the placebo and
a significant less decline in LVEF. The study was stopped
prematurely since further accrual was not felt to likely
change the results. Both interventions had minimal toxicity
compared to placebo. Over 3/4 of the patients were
treated with TCH with the rest having an anthracycline
regimen followed by taxane and trastuzumab.
This year’s meeting may not have reported any major
breakthroughs, but did provide updates to influence clinical
practice and further increased our understanding of breast
cancer and also helped reduce the toxicities of our treat-
ments. The use of bone-protecting agents in patients on
adjuvant AI’s was further consolidated and the use of AI’s in
DCIS was further solidified. When treating a patient with
adjuvant trastuzumab you would probably look for anexcuse to prescribe either a beta-blocker or ACE inhibitor
to reduce the risk of cardiotoxicity. Finally the Create-X
trial does provide us with an option to use post-op capeci-
tabine in patients with residual disease after neo-adjuvant
AC/Taxane. We anxiously await the results of other studies
that are ongoing, which will help answer some of the
questions raised by this year’s presentations.Conflicts of interest
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